Amalgamated Financial’s Intellia Therapeutics NTLA Stock Holding History

Amalgamated Financial’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$830K	Buy	+11,420	New	+$968K	0.01%	1269

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Amalgamated Financial's NTLA Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Intellia Therapeutics (NTLA) in Q1 2022: 11,420 shares worth $830K. The stake represents 0.01% of the portfolio and ranks #1269 among its holdings.

349 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

Amalgamated Financial held 11,420 shares of Intellia Therapeutics worth $830K as of Q1 2022.
Intellia Therapeutics was a new Amalgamated Financial position in Q1 2022.
Intellia Therapeutics made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1269 holding.
349 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.